Mood Disorders

Psychopharmacology

Ketamine in Psychiatric Practice: Taking the Long-Term View

Sunday, October 28
9:00 AM - 10:15 AM
Location: Tangerine WF4

The number of ketamine treatment centers across the United States has grown dramatically over the past several years, despite limited information about ketamine’s longer-term safety and effectiveness for psychiatric disorders. There is no generally accepted treatment protocol beyond the typical 4 to 6 treatments delivered over 2 or more weeks. Because relapse is virtually universal among early responders without continuation therapies, it is imperative that clinicians referring patients for ketamine therapy have a nuanced understanding of the risks and benefits of maintenance therapy. This clinically oriented session will discuss emerging data for ketamine therapy across multiple psychiatric indications, with an expanded focus on longer-term management and relapse prevention.

Sanjay J. Mathew, MD

Professor of Psychiatry and Behavioral Sciences
Baylor College of Medicine and Michael E. Debakey VA Medical Center
Baylor College of Medicine
Houston, TX

Sanjay J. Mathew, MD, is the Johnson Family Chair for Research in Psychiatry in the Menninger Department of Psychiatry & Behavioral Sciences and director of the Mood and Anxiety Disorders Research Program at Baylor College of Medicine. He is also a staff psychiatrist at the Michael E. Debakey VA Medical Center in Houston, Texas. He attended medical school at Baylor College of Medicine and completed his psychiatric residency at Columbia University and the New York State Psychiatric Institute, where he also completed a NIMH T32 research fellowship in affective and anxiety disorders. Dr. Mathew began his faculty career at the Mount Sinai School of Medicine, where he co-founded and directed the Mood and Anxiety Disorders Program. His research program is funded by NIMH, Department of Veterans Affairs, foundations, and industry, and focuses on experimental therapeutics and pathophysiology of depression, trauma, and stress-related disorders. His team has been active in clinical and translational research related to ketamine and rapidly acting antidepressants since 2006.

Dr. Mathew has published more than 100 articles in leading scientific journals and serves on the editorial board of several journals. He is an elected member of the American College of Neuropsychopharmacology and was elected to the Board of the American Society of Clinical Psychopharmacology. He is co-editor with Dr. Carlos Zarate of NIMH of the book, Ketamine for Treatment-Resistant Depression: The First Decade of Progress, published in 2016.

Presentation(s):

Send Email for Sanjay Mathew


Assets

Ketamine in Psychiatric Practice: Taking the Long-Term View



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Ketamine in Psychiatric Practice: Taking the Long-Term View